Summary
Written by a model from the transcript; not yet reviewed.
This episode of Short Wave examines where science stands on reversing human biological aging. Hosts Regina Barber and producer Berly McCoy explore how researchers are moving beyond superficial treatments like skin creams to target the cellular and molecular drivers of aging. Geneticists and neuroscientists explain how epigenetic changes allow cells to lose their identity and malfunction over time, and how applying specific DNA switches can reset a cell back to a youthful state without erasing its identity. The discussion highlights real-world trials, including Life Biosciences dosing the first human patients with an experimental eye drug to reverse age-related vision loss, and Rubito Life Sciences targeting senescent zombie cells in skin to clear lesions and sun damage. Experts weigh in on whether these breakthroughs will ultimately cure age-related diseases or extend human lifespan.
- Scientists use epigenetic clocks to measure biological age, but results can vary widely between different vendors and cell types. 6:21
- Researchers can reverse a cell's age while maintaining its identity by using three specific DNA switches discovered by Shinya Yamanaka. 10:22
- Life Biosciences dosed human patients with an experimental drug to reverse cellular aging in the eye and treat glaucoma. 10:49
- Targeting senescent zombie cells in the skin can clear skin lesions, reduce sun damage, and improve conditions like eczema and psoriasis. 13:20
Chapters
- 0:00Podcast Intro and Sponsor Messages
Hosts introduce the episode and run sponsor ads before diving into the topic.
- 0:58Life Biosciences First Human Eye Trial
Gina recounts the first human trial that reversed aging in eye cells.
- 4:27Science Behind Aging: Epigenetics Explained
Hosts explain how epigenetic changes drive aging and how scientists study them.
- 5:30Life Biosciences Drug Mechanism
Explanation of how the drug uses Yamanaka’s four proteins to reset cells without erasing identity.
- 6:29Epigenetic Clocks and Their Accuracy
Discussion of how epigenetic clocks measure biological age and their limitations.
- 11:07Eye Trial Results and Future Directions
Review of early eye trial outcomes and plans to test other organs.
- 12:42Skin Aging and Zombie Cells
Introduction of skin rejuvenation research targeting senescent cells.
- 13:46Plasma Reversal Attempts
Brief look at attempts to reverse plasma age and why results were short-lived.
- 14:18Implications for Lifespan and Healthspan
Hosts debate whether reversing aging can extend human life and what limits exist.
Highlights
- 0:58
First Human Dosed With Age Reversal Drugdata
A bioscience company dosed the first human ever with a drug designed to reverse aging in a person's eye, shifting focus from cosmetics to disease prevention.
- 6:56
Inconsistencies in Biological Age Testsinsight
Sending blood samples to different epigenetic clock vendors can yield a 25-year predicted biological age gap, showing the current limitations of these tests.
- 9:51
Resetting Cells Without Erasing Identitystrategy
Applying three out of four Yamanaka proteins resets cells to a young, healthy state while keeping heart, lung, and retinal cells specialized.
- 12:26
Clearing Out Damaged Zombie Cellsstrategy
Scientists developed drugs that target non-functional zombie cells and rejuvenate surrounding aged cells in the skin, shrinking wrinkles and clearing lesions.
- 13:57
Rebounding Reversal in Blood Plasmadata
Attempts to reverse the age of human blood plasma showed limited success because the reversal effect rebounded and faded within a few months.
- 14:27
Lifespan Extension Versus Healthspandebate
Researchers debate whether curing age-related diseases will actually extend human lifespans or simply give people a healthier span of life within natural limits.
Quotes
Sponsored segments
- Angi 0:00–0:17
- Saatva 3:06–3:34
- ProLon 3:35–4:04
- Synchrony Bank 4:04–4:16
- Synchrony Bank 16:03–16:15
- Angi 16:17–16:48
About this episode
Reversing aging may sound like science fiction, but scientists have already found a way to do it—at least, theoretically. Based on a 2012 Nobel-prize winning discovery, researchers are testing whether they can revert diseased cells in the eye back to young and healthy ones. They gave people a drug this year. If it works, it’ll open the door to curing and possibly preventing other age-related diseases. And that led producer Berly McCoy https://www.npr.org/people/985775371/berly-mccoy to wonder: Could all this research eventually extend our human lifespans? If you like this episode, check out our episodes on zombie cells http://lnk.to/zuBuCU, why our hair turns gray http://lnk.to/0ps3t8 and why we die http://lnk.to/oosyhs. Interested in more science on aging? Email us your question at [email protected] mailto:[email protected]. Support public media with NPR+ and enjoy perks for over 25 podcasts like this one. This show’s perks include sponsor-free listening. Learn more at plus.npr.org http://plus.npr.org. See pcm.adswizz.com https://pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences. NPR Privacy Policy https://www.npr.org/about-npr/179878450/privacy-policy
Transcript
2,809 words · 8 speakers
Speaker names marked are inferred from speaking time and the show’s known hosts — they are not voice-verified.
Topics
- Life Biosciences
- NPR
- epigenetic clocks
- zombie cells
- Rubito Life Sciences
- USC's Longevity Institute
- Stanford School of Medicine
- Buck Institute for Research on Aging
- glaucoma
Page updated · transcript and summary are machine-generated